Loxo Oncology, which is developing small molecule therapeutics for the treatment of solid tumors, filed on Monday with the SEC to raise up to $69 million in an initial public offering. The Stamford, CT-based company, which was founded in 2013, plans to list on the NASDAQ under the symbol LOXO. Loxo Oncology initially filed confidentially on May 14, 2014. Cowen & Company and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
